STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2180 by analyst upside · 2026-06-27
DFTX
Definium Therapeutics, Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+24.6%
implied upside to consensus target
Current Price $44.95
Consensus Target $56.0
Bull Target $74.0
Bear Target $30.0
Analysts Covering 15
ANALYST CONSENSUS — BUY
Strong Buy
3
Buy
12
Hold
0
Sell
0
52-Week Low $6.4
52-Week High $47.01
YTD Return +229.5%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E -28.8x
EPS (TTM) $-2.50
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $6.4
52-Week High $47.01
Current Price $44.95
Bear Target $30.0
Bull Target $74.0
● Now $44.95 ● Target $56.0
TRADING DATA
Avg Volume 2.6M
YTD Return +229.5%
Analyst Count 15
Consensus Buy
Upside to Target +24.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Definium Therapeutics, Inc. (DFTX) is currently trading at $44.95 with a Wall Street consensus price target of $56.0, implying potential upside of 24.6% over the next 12 months. 15 analysts currently cover DFTX, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $74.0, while the most cautious has a target of $30.0.

DFTX operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 229.5% year-to-date and is currently trading near the upper end of its 52-week range of $6.4 – $47.01.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for DFTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-06-16 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-08 14% win rate (7 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2026-04-22 29% win rate (7 calls)
Stifel ● Initiated
Buy 2026-04-17 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-04-16 Building track record
Piper Sandler ● Initiated
Overweight 2026-04-10 14% win rate (7 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-02 31% win rate (48 calls)
Wolfe Research ● Initiated
Outperform 2026-02-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →